Complete Filing Data
AbCellera Biologics Inc. reported Stockholders Equity of $966.90 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean AbCellera Biologics Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income * | -$146.4M | -$162.9M | -$146.4M | $158.5M | $153.5M | $118.9M | -$2.2M |
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | $144.0K | -$2.7M | -$329.0K | -$1.7M | $280.0K | ||
| Revenue From Contract With Customer Excluding Assessed Tax | $75.1M | $28.8M | $38.0M | $485.4M | $375.2M | $233.2M | $11.6M |
| Research And Development Expense | $186.8M | $167.3M | $175.7M | $107.9M | $62.1M | $29.4M | $10.1M |
| Other Nonoperating Income Expense | -$2.7M | $62.3M | $6.8M | -$4.0M | -$6.1M | -$6.8M | -$209.0K |
| Operating Income Loss | -$217.1M | -$314.8M | -$237.2M | $216.5M | $204.4M | $156.0M | -$4.1M |
| Operating Expenses | $292.2M | $343.6M | $275.2M | $268.9M | $170.8M | $77.1M | $15.7M |
| Nonoperating Income Expense | $39.5M | $114.4M | $63.2M | $22.6M | $14.7M | $1.8M | $1.9M |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$177.6M | -$200.4M | -$174.0M | $239.1M | $219.1M | $157.8M | -$2.2M |
| General And Administrative Expense | $83.2M | $85.5M | $75.2M | $55.5M | $41.8M | $11.9M | $2.7M |
| Comprehensive Income Net Of Tax | -$146.3M | -$165.5M | -$146.7M | $156.8M | $153.7M | $118.9M | -$2.2M |
| Selling And Marketing Expense | $12.8M | $14.2M | $11.3M | $6.9M | $3.8M | $1.3M | |
| Income Tax Expense Benefit | -$31.2M | -$37.5M | -$27.6M | $80.6M | $65.7M | $38.9M | |
| Deferred Income Tax Liabilities Net | $9.1M | $10.1M | $30.6M | $33.2M | $37.4M | $26.2M | |
| Amortization Of Intangible Assets | $10.1M | $2.5M | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$57.1M | -$34.7M | -$45.6M | -$51.1M | -$36.9M | -$40.6M | -$28.6M | -$30.5M | -$40.1M | $26.6M | -$6.8M | $168.6M | -$21.4M | -$2.3M | $117.2M | -$2.7M | $6.7M | -$2.1M |
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | -$41.0K | $4.3M | -$2.6M | $841.0K | -$257.0K | -$96.0K | $439.0K | $122.0K | -$630.0K | -$1.3M | -$211.0K | $507.0K | -$1.5M | $2.2M | ||||
| Revenue From Contract With Customer Excluding Assessed Tax | $9.0M | $17.1M | $4.2M | $6.5M | $7.3M | $10.0M | $6.6M | $10.1M | $12.2M | $101.4M | $45.9M | $316.6M | $5.5M | $27.6M | $202.7M | $9.4M | $11.2M | $4.7M |
| Research And Development Expense | $55.0M | $39.2M | $42.5M | $41.0M | $40.9M | $39.3M | $37.9M | $36.5M | $52.6M | $26.6M | $26.7M | $26.4M | $17.5M | $15.0M | $12.4M | $7.5M | $9.1M | $4.1M |
| Other Nonoperating Income Expense | -$2.0M | $2.0M | -$2.5M | $17.9M | $32.2M | -$1.5M | $2.0M | -$2.0M | $3.6M | $1.1M | -$1.4M | $0.00 | -$1.3M | $314.0K | $265.0K | -$2.3M | -$293.0K | -$1.0M |
| Operating Income Loss | -$76.3M | -$49.6M | -$62.7M | -$93.7M | -$93.5M | -$54.9M | -$54.9M | -$51.4M | -$64.9M | $37.7M | -$8.4M | $225.0M | -$28.1M | -$7.0M | $158.1M | -$1.8M | -$854.0K | -$2.1M |
| Operating Expenses | $85.2M | $66.7M | $66.9M | $100.2M | $100.8M | $64.8M | $61.5M | $61.4M | $77.1M | $63.6M | $54.3M | $91.6M | $33.6M | $34.7M | $44.7M | $11.1M | $12.1M | $6.8M |
| Nonoperating Income Expense | $7.5M | $13.2M | $9.7M | $31.0M | $45.3M | $12.1M | $15.6M | $13.4M | $16.7M | $8.9M | $1.5M | $5.9M | $3.1M | $5.0M | $3.4M | -$925.0K | $7.6M | $29.0K |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$68.8M | -$36.3M | -$53.0M | -$62.6M | -$48.2M | -$42.7M | -$39.3M | -$38.0M | -$48.1M | $46.6M | -$6.9M | $230.8M | -$25.0M | -$2.1M | $161.5M | -$2.7M | $6.7M | -$2.1M |
| General And Administrative Expense | $22.1M | $19.0M | $16.2M | $19.1M | $20.2M | $17.4M | $14.4M | $15.5M | $15.1M | $13.8M | $14.4M | $14.3M | $11.3M | $11.2M | $6.4M | $3.0M | $1.5M | $1.7M |
| Comprehensive Income Net Of Tax | -$57.2M | -$30.4M | -$48.2M | -$50.3M | -$37.2M | -$40.7M | -$28.2M | -$30.4M | -$40.7M | $25.3M | -$7.0M | $169.1M | -$22.9M | -$171.0K | $117.2M | -$2.7M | $6.7M | |
| Selling And Marketing Expense | $2.9M | $3.0M | $2.8M | $3.1M | $3.1M | $3.4M | $3.5M | $3.8M | $3.8M | $3.1M | $3.1M | $2.4M | $1.2M | $1.3M | $2.6M | $626.0K | $547.0K | $437.0K |
| Income Tax Expense Benefit | -$11.6M | -$1.6M | -$7.4M | -$11.5M | -$11.3M | -$2.1M | -$10.7M | -$7.5M | -$8.0M | $20.0M | -$101.0K | $62.2M | -$3.6M | $250.0K | $44.3M | |||
| Deferred Income Tax Liabilities Net | $9.7M | $10.1M | $10.1M | $12.8M | $21.7M | $30.3M | $33.2M | $33.2M | $33.4M | $34.1M | $34.6M | $36.8M | $36.2M | $25.5M | $27.0M | |||
| Amortization Of Intangible Assets | $922.0K | $1.7M | $2.7M | $2.6M | $2.5M | $158.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $966.9M | $1.06B | $1.15B | $1.23B | $1.03B | $830.5M | $10.3M | $11.6M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $155.2M | $183.6M | $160.6M | $414.7M | $501.1M | $594.1M | $7.6M | $10.4M |
| Cash And Cash Equivalents At Carrying Value | $61.8M | $55.6M | $133.3M | $44.9M | $8.2M | $594.1M | ||
| Operating Lease Right Of Use Asset Amortization Expense | $6.7M | $6.1M | $6.5M | $5.3M | $2.8M | $435.0K | $243.0K | |
| Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation | $76.1M | $1.9M | $1.2M | $50.7M | $36.6M | $1.7M | $2.8M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$28.4M | $23.0M | -$254.0M | -$86.5M | -$93.0M | $586.6M | -$2.9M | |
| Intangible Assets Net Excluding Goodwill | $38.4M | $42.1M | $120.4M | $131.5M | $148.4M | $115.2M | $0.00 | |
| Goodwill | $47.8M | $47.8M | $47.8M | $47.8M | $47.8M | $31.5M | ||
| Retained Earnings Accumulated Deficit | -$29.5M | $116.9M | $279.8M | $426.2M | $267.7M | $114.2M | ||
| Other Liabilities Noncurrent | $4.8M | $7.2M | $5.9M | $3.1M | $1.7M | $6.6M | ||
| Other Assets Noncurrent | $51.9M | $96.5M | $94.2M | $46.3M | $30.6M | $8.4M | ||
| Other Assets Current | $111.1M | $67.1M | $55.8M | $75.4M | $21.2M | $6.0M | ||
| Operating Lease Liability Noncurrent | $137.4M | $60.7M | $71.2M | $76.7M | $36.4M | $3.7M | ||
| Liabilities Noncurrent | $325.7M | $227.9M | $216.8M | $189.3M | $172.2M | $71.5M | ||
| Liabilities Current | $64.3M | $76.6M | $119.0M | $118.3M | $120.7M | $103.5M | ||
| Liabilities And Stockholders Equity | $1.36B | $1.36B | $1.49B | $1.54B | $1.32B | $1.01B | ||
| Liabilities | $390.0M | $304.5M | $335.8M | $307.6M | $292.8M | $175.0M | ||
| Investments In Affiliates Subsidiaries Associates And Joint Ventures | $62.6M | $82.3M | $65.9M | $72.5M | $50.3M | $19.2M | ||
| Contract With Customer Liability Current | $13.5M | $13.5M | $19.0M | $21.6M | $7.5M | $6.6M | ||
| Common Stock Value | $802.3M | $777.2M | $753.2M | $734.4M | $722.4M | $710.4M | ||
| Business Combination Contingent Consideration Liability Current | $0.00 | $8.1M | $50.5M | $44.2M | $22.9M | $13.4M | ||
| Assets Noncurrent | $628.7M | $609.2M | $616.1M | $515.4M | $388.8M | $192.2M | ||
| Assets Current | $728.2M | $751.4M | $872.0M | $1.03B | $929.8M | $813.3M | ||
| Assets | $1.36B | $1.36B | $1.49B | $1.54B | $1.32B | $1.01B | ||
| Additional Paid In Capital Common Stock | $198.3M | $166.4M | $121.1M | $74.1M | $35.4M | $5.9M | ||
| Non Cash Or Part Non Cash Acquisition Property And Equipment Purchases In Accounts Payable | $2.0M | $12.8M | $13.6M | $5.9M | $5.4M | $656.0K | $35.0K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $153.5M | $181.3M | $158.3M | $411.5M | $501.1M | $594.1M | ||
| Accounts And Accrued Receivable Current | $58.3M | $33.6M | $30.6M | $38.6M | $160.6M | $213.2M | ||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$4.2M | -$4.4M | -$1.7M | -$1.4M | $280.0K | |||
| Available For Sale Securities Debt Securities | $405.3M | $469.3M | $627.3M | $500.0M | $246.8M | |||
| Business Combination Contingent Consideration Liability Noncurrent | $0.00 | $4.9M | $16.1M | $35.9M | $9.1M | |||
| Restricted Cash And Cash Equivalents Noncurrent | $1.7M | $2.3M | $2.3M | $3.1M | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $964.0M | $1.01B | $1.02B | $1.08B | $1.11B | $1.13B | $1.18B | $1.19B | $1.21B | $1.25B | $1.21B | $1.21B | $953.4M | $967.7M | $957.1M | $89.3M | $90.9M | $83.7M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $110.4M | $119.7M | $186.6M | $153.9M | $175.6M | $150.9M | $199.7M | $207.0M | $220.3M | $400.1M | $817.4M | $571.7M | $517.7M | $792.6M | $685.8M | $91.1M | $113.1M | $88.9M |
| Cash And Cash Equivalents At Carrying Value | $83.2M | $92.4M | $159.3M | $126.6M | $148.3M | $123.6M | $172.4M | $179.7M | $193.0M | $372.0M | $790.6M | $545.7M | $517.7M | $792.6M | $685.8M | |||
| Operating Lease Right Of Use Asset Amortization Expense | $1.3M | $1.9M | $1.6M | $976.0K | $661.0K | $73.0K | ||||||||||||
| Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation | $3.4M | $107.0K | $2.1M | $658.0K | $14.2M | $741.0K | ||||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $2.9M | -$9.7M | -$194.3M | $70.5M | $91.7M | $81.4M | ||||||||||||
| Intangible Assets Net Excluding Goodwill | $39.3M | $40.3M | $41.2M | $52.6M | $85.7M | $118.7M | $124.1M | $126.7M | $128.8M | $142.5M | $143.2M | $145.8M | $148.8M | $110.2M | $112.7M | |||
| Goodwill | $47.8M | $47.8M | $47.8M | $47.8M | $47.8M | $47.8M | $47.8M | $47.8M | $47.8M | $47.8M | $47.8M | $47.8M | $49.5M | $31.5M | $31.5M | |||
| Retained Earnings Accumulated Deficit | -$20.5M | $36.6M | $71.3M | $151.1M | $202.2M | $239.2M | $326.9M | $355.5M | $386.1M | $456.1M | $429.5M | $436.2M | $207.7M | $229.1M | $231.4M | |||
| Other Liabilities Noncurrent | $1.4M | $1.6M | $1.6M | $1.5M | $6.3M | $5.7M | $5.1M | $2.3M | $3.0M | $2.9M | $3.0M | $3.4M | $1.7M | $1.7M | $931.0K | |||
| Other Assets Noncurrent | $53.1M | $57.5M | $61.6M | $134.2M | $112.5M | $104.9M | $80.7M | $113.4M | $89.8M | $49.1M | $43.8M | $43.4M | $31.6M | $15.9M | $9.5M | |||
| Other Assets Current | $133.0M | $116.8M | $94.7M | $43.4M | $40.1M | $56.5M | $71.2M | $64.4M | $99.2M | $46.5M | $43.9M | $28.9M | $6.6M | $6.5M | $5.7M | |||
| Operating Lease Liability Noncurrent | $137.1M | $137.2M | $63.2M | $66.3M | $66.5M | $68.1M | $75.2M | $78.1M | $77.3M | $71.6M | $32.8M | $36.4M | $27.3M | $31.0M | $17.0M | |||
| Liabilities Noncurrent | $323.2M | $328.0M | $245.8M | $235.2M | $231.1M | $228.3M | $219.2M | $223.4M | $199.8M | $196.2M | $159.8M | $171.4M | $169.8M | $114.4M | $83.0M | |||
| Liabilities Current | $68.8M | $67.0M | $75.4M | $79.6M | $70.4M | $104.9M | $110.2M | $118.9M | $89.6M | $106.1M | $221.1M | $213.4M | $49.5M | $69.8M | $88.4M | |||
| Liabilities And Stockholders Equity | $1.36B | $1.40B | $1.34B | $1.39B | $1.41B | $1.46B | $1.51B | $1.54B | $1.50B | $1.55B | $1.59B | $1.59B | $1.17B | $1.15B | $1.13B | |||
| Liabilities | $392.0M | $395.0M | $321.2M | $314.7M | $301.5M | $333.2M | $329.4M | $342.3M | $289.4M | $302.2M | $380.9M | $384.8M | $219.3M | $184.2M | $171.4M | |||
| Investments In Affiliates Subsidiaries Associates And Joint Ventures | $93.3M | $90.4M | $81.6M | $84.1M | $76.1M | $71.6M | $62.9M | $58.8M | $57.6M | $66.7M | $65.8M | $58.9M | $47.5M | $42.7M | $32.2M | |||
| Contract With Customer Liability Current | $15.7M | $16.9M | $18.8M | $5.6M | $6.4M | $10.6M | $17.5M | $8.5M | $11.8M | $6.8M | $4.6M | $9.2M | $6.2M | $10.6M | $11.3M | |||
| Common Stock Value | $794.5M | $791.7M | $790.1M | $772.8M | $770.0M | $764.6M | $747.9M | $744.8M | $742.8M | $730.4M | $726.8M | $725.8M | $718.1M | $714.8M | $711.1M | |||
| Business Combination Contingent Consideration Liability Current | $0.00 | $0.00 | $8.8M | $20.2M | $20.0M | $51.4M | $53.9M | $54.9M | $42.9M | $32.5M | $34.3M | $27.5M | $12.1M | $11.6M | $13.8M | |||
| Assets Noncurrent | $660.9M | $659.9M | $579.2M | $649.9M | $640.9M | $649.1M | $592.7M | $606.4M | $557.3M | $506.7M | $449.8M | $417.9M | $369.0M | $287.9M | $220.5M | |||
| Assets Current | $695.1M | $742.1M | $765.0M | $742.9M | $771.6M | $813.9M | $919.5M | $930.7M | $940.7M | $1.05B | $1.14B | $1.17B | $803.7M | $864.0M | $908.0M | |||
| Assets | $1.36B | $1.40B | $1.34B | $1.39B | $1.41B | $1.46B | $1.51B | $1.54B | $1.50B | $1.55B | $1.59B | $1.59B | $1.17B | $1.15B | $1.13B | |||
| Additional Paid In Capital Common Stock | $192.8M | $181.5M | $168.6M | $155.4M | $140.8M | $128.0M | $109.4M | $96.4M | $81.6M | $64.4M | $56.0M | $44.7M | $26.9M | $21.7M | $14.6M | |||
| Non Cash Or Part Non Cash Acquisition Property And Equipment Purchases In Accounts Payable | $11.0M | $18.7M | $8.9M | $2.4M | $423.0K | |||||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $108.2M | $117.4M | $184.3M | $151.6M | $173.3M | $148.6M | $197.4M | $204.7M | $218.0M | $397.0M | $815.6M | $570.7M | $517.7M | $792.6M | $685.8M | |||
| Accounts And Accrued Receivable Current | $41.5M | $47.3M | $40.0M | $31.4M | $36.1M | $34.4M | $37.4M | $45.7M | $20.0M | $106.0M | $52.8M | $334.4M | $43.6M | |||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$2.7M | -$2.7M | -$7.0M | -$1.2M | -$2.1M | -$1.8M | -$1.5M | -$1.9M | -$2.0M | -$717.0K | $576.0K | $787.0K | $644.0K | $2.2M | ||||
| Available For Sale Securities Debt Securities | $412.5M | $460.6M | $446.0M | $516.5M | $522.0M | $574.5M | $613.4M | $615.9M | $603.5M | $496.2M | $231.7M | $240.3M | $235.8M | |||||
| Business Combination Contingent Consideration Liability Noncurrent | $4.4M | $4.4M | $5.1M | $5.3M | $5.8M | $15.7M | $25.4M | $24.6M | $30.6M | $44.9M | $9.6M | $9.4M | ||||||
| Restricted Cash And Cash Equivalents Noncurrent | $2.3M | $2.3M | $2.3M | $2.3M | $2.3M | $2.3M | $2.3M | $2.3M | $2.3M | $3.1M | $1.8M | $937.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Share Based Compensation | $55.8M | $67.6M | $64.2M | $49.5M | $30.6M | $8.4M | $890.0K |
| Payments To Acquire Property Plant And Equipment | $42.8M | $78.4M | $76.9M | $70.7M | $58.5M | $9.7M | $4.0M |
| Net Cash Provided By Used In Operating Activities | -$131.3M | -$108.6M | -$43.9M | $277.4M | $244.6M | $22.7M | $2.7M |
| Net Cash Provided By Used In Investing Activities | $87.8M | $121.4M | -$221.1M | -$352.6M | -$332.2M | -$119.8M | -$5.8M |
| Net Cash Provided By Used In Financing Activities | $14.1M | $12.8M | $10.4M | -$1.6M | -$3.9M | $683.7M | $195.0K |
| Increase Decrease In Receivables | $55.6M | $75.1M | $45.9M | $22.7M | $37.4M | $5.5M | $1.8M |
| Increase Decrease In Deferred Revenue | -$2.2M | -$7.9M | -$14.0M | $6.2M | $8.6M | $21.8M | -$6.0K |
| Increase Decrease In Deferred Grant Income | $3.6M | -$34.0M | -$39.5M | -$9.3M | -$30.7M | $6.8M | |
| Increase Decrease In Accrued Income Taxes Payable | -$29.8M | $6.7M | $30.5M | -$88.6M | -$13.5M | $36.4M | |
| Payments To Acquire Equity Method Investments | $7.1M | $19.6M | $13.7M | $25.7M | $30.3M | $19.2M | |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $1.1M | -$2.6M | $589.0K | -$9.6M | -$1.4M | ||
| Proceeds From Receipt Of Grant Funding | $21.3M | $35.7M | $25.3M | $16.4M | $32.6M | ||
| Increase Decrease In Other Operating Assets | -$17.1M | -$6.0M | -$18.3M | $1.4M | $3.4M | ||
| Proceeds From Sale And Maturity Of Marketable Securities | $506.1M | $937.9M | $910.9M | $510.6M | $27.6M | ||
| Payments To Acquire Marketable Securities | $436.0M | $765.1M | $1.02B | $764.0M | $274.7M | ||
| Increase Decrease In Accrued Royalties Receivable | $0.00 | -$9.3M | -$129.2M | -$59.9M | $197.6M | ||
| Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Royalties Payable | $1.1M | $1.4M | $6.6M | $150.0K | |||
| Increase Decrease In Royalties Payable | -$3.2M | -$4.6M | $27.1M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|---|---|
| Share Based Compensation | $14.8M | $17.4M | $15.5M | $12.3M | $5.4M | $1.2M |
| Payments To Acquire Property Plant And Equipment | $10.6M | $24.1M | $15.0M | $14.5M | $3.6M | $583.0K |
| Net Cash Provided By Used In Operating Activities | -$11.6M | -$41.7M | -$44.1M | $100.2M | $109.5M | -$764.0K |
| Net Cash Provided By Used In Investing Activities | $7.9M | $29.9M | -$149.6M | -$26.4M | -$15.8M | -$5.6M |
| Net Cash Provided By Used In Financing Activities | $6.0M | $2.8M | -$458.0K | -$3.1M | -$1.5M | $87.7M |
| Increase Decrease In Receivables | $1.1M | $18.6M | -$7.9M | $8.8M | $30.1M | $26.6M |
| Increase Decrease In Deferred Revenue | $13.3M | -$8.0M | -$3.9M | $941.0K | $6.1M | $27.7M |
| Increase Decrease In Deferred Grant Income | $1.2M | -$11.3M | -$4.5M | -$4.7M | -$2.5M | |
| Increase Decrease In Accrued Income Taxes Payable | -$4.4M | -$3.2M | -$12.6M | $70.0M | -$6.1M | |
| Payments To Acquire Equity Method Investments | $1.9M | $5.9M | $4.5M | $8.3M | $12.2M | |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $590.0K | -$781.0K | -$213.0K | -$204.0K | -$484.0K | |
| Proceeds From Receipt Of Grant Funding | $1.0M | $7.2M | $2.7M | $2.6M | ||
| Increase Decrease In Other Operating Assets | -$7.3M | $3.6M | $6.1M | $7.6M | $4.4M | |
| Proceeds From Sale And Maturity Of Marketable Securities | $190.0M | $306.5M | $262.6M | $57.3M | ||
| Payments To Acquire Marketable Securities | $165.0M | $249.4M | $360.8M | $51.8M | ||
| Increase Decrease In Accrued Royalties Receivable | $0.00 | -$9.3M | $167.9M | -$26.9M | ||
| Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Royalties Payable | -$4.9M | -$5.8M | $751.0K | -$5.2M | -$156.0K | |
| Increase Decrease In Royalties Payable | $0.00 | -$16.3M | $22.9M | -$7.1M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 298.7M | 294.3M | 289.2M | 285.1M | 275.8M | 159.2M | 151.3M |
| Weighted Average Number Of Diluted Shares Outstanding | 298.7M | 294.3M | 289.2M | 314.8M | 318.3M | 263.1M | 151.3M |
| Earnings Per Share Diluted | $-0.49 | $-0.55 | $-0.51 | $0.50 | $0.48 | $0.45 | $-0.01 |
| Earnings Per Share Basic | $-0.49 | $-0.55 | $-0.51 | $0.56 | $0.56 | $0.53 | $-0.01 |
| Common Stock Shares Outstanding | 300.6M | 295.8M | 290.8M | 286.9M | 283.3M | 269.5M | |
| Common Stock Shares Issued | 300.6M | 295.8M | 290.8M | 286.9M | 283.3M | 269.5M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 298.9M | 298.5M | 297.7M | 294.9M | 294.2M | 292.7M | 289.5M | 288.9M | 287.8M | 285.3M | 284.7M | 283.9M | 278.9M | 272.2M | 269.7M | 153.0M | 152.3M | 151.9M |
| Weighted Average Number Of Diluted Shares Outstanding | 298.9M | 298.5M | 297.7M | 294.9M | 294.2M | 292.7M | 289.5M | 288.9M | 287.8M | 315.8M | 284.7M | 311.5M | 278.9M | 272.2M | 320.3M | 153.0M | 260.8M | 151.9M |
| Earnings Per Share Diluted | $-0.19 | $-0.12 | $-0.15 | $-0.17 | $-0.13 | $-0.14 | $-0.10 | $-0.11 | $-0.14 | $0.08 | $-0.02 | $0.54 | $-0.08 | $-0.01 | $0.37 | $-0.02 | $0.03 | $-0.01 |
| Earnings Per Share Basic | $-0.19 | $-0.12 | $-0.15 | $-0.17 | $-0.13 | $-0.14 | $-0.10 | $-0.11 | $-0.14 | $0.09 | $-0.02 | $0.59 | $-0.08 | $-0.01 | $0.43 | $-0.02 | $0.03 | $-0.01 |
| Common Stock Shares Outstanding | 299.0M | 295.8M | 295.8M | 290.8M | 290.8M | 290.8M | 286.9M | 286.9M | 286.9M | 285.8M | 285.1M | 284.5M | 281.2M | 277.0M | 270.9M | |||
| Common Stock Shares Issued | 299.0M | 295.8M | 295.8M | 290.8M | 290.8M | 290.8M | 286.9M | 286.9M | 286.9M | 285.8M | 285.1M | 284.5M | 281.2M | 277.0M | 270.9M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $56.3M | $67.6M | $64.2M | $49.5M | $29.2M | $4.1M | $840.0K |
| Grants And Incentives | $13.9M | $13.6M | $14.2M | $10.6M | $17.5M | $8.3M | $1.8M |
| Depreciation | $18.4M | $12.5M | $12.8M | $9.0M | $4.4M | $2.3M | $1.6M |
| Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised | $806.0K | $1.7M | $1.6M | $1.2M | $6.6M | ||
| Depreciation And Amortization | $24.4M | $27.8M | $14.5M | $4.8M | $1.6M | ||
| Investment Income Interest | $28.3M | $38.5M | $42.2M | $16.1M | $3.3M | $293.0K | $155.0K |
| Other Noncash Income Expense | $3.3M | $19.7M | -$2.2M | -$3.3M | -$1.3M | -$4.7M | -$194.0K |
| Royalty Expense | $0.00 | $0.00 | $66.4M | $45.5M | $27.1M | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $14.0M | $14.4M | $15.0M | $17.2M | $17.8M | $17.4M | $15.9M | $16.4M | $15.5M | $11.8M | $12.1M | $12.3M | $7.7M | $8.5M | $4.0M | $56.0K | $464.0K | $744.0K |
| Grants And Incentives | $2.7M | $3.7M | $4.2M | $3.5M | $3.3M | $3.3M | $2.8M | $4.6M | $3.4M | $2.2M | $1.5M | $5.2M | $4.4M | $4.6M | $3.1M | $1.3M | $7.9M | $1.0M |
| Depreciation | $4.3M | $4.5M | $4.4M | $3.8M | $3.4M | $3.2M | $3.1M | $3.0M | $2.9M | $2.5M | $2.3M | $1.4M | $1.2M | $1.1M | $840.0K | $0.00 | $1.1M | $415.0K |
| Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised | $114.0K | $73.0K | $151.0K | $228.0K | $460.0K | $892.0K | $257.0K | $334.0K | $489.0K | $231.0K | $232.0K | $403.0K | ||||||
| Depreciation And Amortization | $5.2M | $5.5M | $5.3M | $36.9M | $36.5M | $4.8M | $5.7M | $5.6M | $5.5M | $5.2M | $4.9M | $4.0M | $3.7M | $3.5M | $3.3M | $41.0K | $893.0K | $574.0K |
| Investment Income Interest | $6.8M | $7.6M | $8.1M | $9.6M | $9.8M | $10.4M | $10.7M | $10.8M | $9.8M | $5.6M | $1.4M | $665.0K | ||||||
| Other Noncash Income Expense | -$1.7M | $3.6M | $592.0K | -$432.0K | $28.0K | |||||||||||||
| Royalty Expense | $0.00 | $0.00 | $0.00 | $15.0M | $5.2M | $44.6M | $0.00 | $3.6M | $20.0M |
Most recent annual filing with the SEC: February 24, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.